Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Healthy males.~2. Complete medical history, including physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests.~3. Aged 21 to 50 years.~4. Body mass index below or equal to 30.~5. Body weight 65 to 95 kg, inclusive.~Exclusion criteria:~1. Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance.~2. Any evidence of a clinically relevant concomitant disease, as judged by the investigator.~3. History of relevant orthostatic hypotension, fainting spells, or blackouts.~4. Chronic or relevant acute infections.~5. History of relevant allergy/hypersensitivity (including allergy to the study medications or its excipients).~6. Intake of prescribed or over-the-counter drugs within less than 6 half-lives of the respective drug prior to study drug administration or during the trial.~7. Participation in another trial with a study medication within two months prior to administration or during the trial (six half-lives).~8. Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day).~9. Inability to refrain from smoking during days of confinement at the study center.~10. Current alcohol abuse as judged by the investigator.~11. Current drug abuse, as judged by the investigator.

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- BI 695502 (Type: EXPERIMENTAL): Subject to receive one intravenous (i.v.) infusion of BI 695502
- bevacizumab A (Type: ACTIVE_COMPARATOR): Subject to receive one i.v. infusion of bevacizumab
- bevacizumab B (Type: ACTIVE_COMPARATOR): Subject to receive one i.v. infusion of bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).